FI20050753A - Uudet peptidit - Google Patents

Uudet peptidit Download PDF

Info

Publication number
FI20050753A
FI20050753A FI20050753A FI20050753A FI20050753A FI 20050753 A FI20050753 A FI 20050753A FI 20050753 A FI20050753 A FI 20050753A FI 20050753 A FI20050753 A FI 20050753A FI 20050753 A FI20050753 A FI 20050753A
Authority
FI
Finland
Prior art keywords
seq
srfkvwwaag
srfkvwwg
arfkvwwa
arfkvwwgg
Prior art date
Application number
FI20050753A
Other languages
English (en)
Swedish (sv)
Other versions
FI20050753A0 (fi
Inventor
Ulf-Haakan Stenman
Jari Leinonen
Ale Naervaenen
Original Assignee
Licentia Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Licentia Oy filed Critical Licentia Oy
Publication of FI20050753A0 publication Critical patent/FI20050753A0/fi
Priority to AT05779484T priority Critical patent/ATE536366T1/de
Priority to EP10185606A priority patent/EP2343311A3/en
Priority to US11/661,691 priority patent/US20090214427A1/en
Priority to EP05779484A priority patent/EP1799701B1/en
Priority to PCT/FI2005/000379 priority patent/WO2006024694A2/en
Publication of FI20050753A publication Critical patent/FI20050753A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
FI20050753A 2004-09-03 2005-07-14 Uudet peptidit FI20050753A (fi)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AT05779484T ATE536366T1 (de) 2004-09-03 2005-09-05 Peptidinhibitoren von hk2 und deren anwendung
EP10185606A EP2343311A3 (en) 2004-09-03 2005-09-05 Peptide inhibitors of HK2 and their use
US11/661,691 US20090214427A1 (en) 2004-09-03 2005-09-05 Novel peptides
EP05779484A EP1799701B1 (en) 2004-09-03 2005-09-05 Peptide inhibitors of hk2 and their use.
PCT/FI2005/000379 WO2006024694A2 (en) 2004-09-03 2005-09-05 Peptide inhibitors of hk2 and their use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60691604P 2004-09-03 2004-09-03

Publications (2)

Publication Number Publication Date
FI20050753A0 FI20050753A0 (fi) 2005-07-14
FI20050753A true FI20050753A (fi) 2006-03-04

Family

ID=34807287

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20050753A FI20050753A (fi) 2004-09-03 2005-07-14 Uudet peptidit

Country Status (5)

Country Link
US (1) US20090214427A1 (fi)
EP (2) EP1799701B1 (fi)
AT (1) ATE536366T1 (fi)
FI (1) FI20050753A (fi)
WO (1) WO2006024694A2 (fi)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
SI2331694T1 (sl) 2008-07-31 2016-09-30 Anglo Netherlands Grain Bv Sončnične rastline odporne na herbicide
LT2734551T (lt) * 2011-07-24 2018-04-10 Cure Tech Ltd. Humanizuotų imunomoduliuojančių monokloninių antikūnų variantai
EP3418294A1 (en) * 2012-09-07 2018-12-26 Agency For Science, Technology And Research Tetrabranched peptides and analogues as a new class of antimicrobials and their preparation thereof
US20170030898A1 (en) * 2015-06-23 2017-02-02 Massachusetts Institute Of Technology Characterization and Directed Evolution of a Methyl Binding Domain Protein for High-Sensitivity DNA Methylation Analysis
US11560418B2 (en) 2015-10-20 2023-01-24 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor IX fusion proteins

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US5037630A (en) 1985-01-14 1991-08-06 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4965392A (en) 1987-03-26 1990-10-23 Neorx Corporation Chelating compounds for metal-radionuclide labeled proteins
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US5849571A (en) 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
JP2934077B2 (ja) 1990-10-20 1999-08-16 株式会社シマノ 自転車用動作装置に対する操作力取出装置
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5879934A (en) 1992-07-31 1999-03-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5661033A (en) 1992-11-25 1997-08-26 The Board Of Trustees Of The Leland Stanford Junior University Gene transfer using herpes virus vectors as a tool for neuroprotection
US5879657A (en) 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
DE69433592T2 (de) 1993-11-09 2005-02-10 Targeted Genetics Corp., Seattle Die erzielung hoher titer des rekombinanten aav-vektors
FR2716682B1 (fr) 1994-01-28 1996-04-26 Centre Nat Rech Scient Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5686278A (en) 1994-03-25 1997-11-11 Indiana University Foundation Methods for enhanced retrovirus-mediated gene transfer
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
FR2732357B1 (fr) 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
US5830725A (en) 1995-04-28 1998-11-03 The Board Of Trustees For The Leland Stanford Junior University Rapid, stable high-titre production of recombing retrovirus
US5773289A (en) 1995-06-06 1998-06-30 University Of Pittsburgh AAV directed targeted integration
US5622856A (en) 1995-08-03 1997-04-22 Avigen High efficiency helper system for AAV vector production
US5830727A (en) 1995-11-18 1998-11-03 Human Gene Therapy Research Institute Herpes simplex virus amplicon mini-vector gene transfer system
US5770414A (en) 1996-02-20 1998-06-23 The Regents Of The University Of California Regulatable retrovirus system for genetic modification of cells
CA2277519A1 (en) 1997-01-10 1998-07-16 Massachusetts Institute Of Technology Treatments for neurotoxicity in alzheimer's disease by .beta.-amyloid peptides
US6610836B1 (en) * 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics

Also Published As

Publication number Publication date
EP1799701A2 (en) 2007-06-27
EP1799701B1 (en) 2011-12-07
EP2343311A2 (en) 2011-07-13
FI20050753A0 (fi) 2005-07-14
US20090214427A1 (en) 2009-08-27
EP2343311A3 (en) 2011-09-07
WO2006024694A3 (en) 2006-08-31
WO2006024694A2 (en) 2006-03-09
ATE536366T1 (de) 2011-12-15

Similar Documents

Publication Publication Date Title
DE60327786D1 (de) Kdr-peptide und diese enthaltende impfstoffe
MX2008009493A (es) Peptido novedoso y uso del mismo.
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
FI20050753A0 (fi) Uudet peptidit
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
HK1128924A1 (en) Sparc-derived cancer rejection antigen peptide and pharmaceutical comprising the same sparc
WO2002097030A3 (en) Peptides derived from neural thread proteins and their medical use
WO2005123760A3 (en) Treating cancer
RS51325B (sr) Polipeptidi koji imaju antimikrobno dejstvo i polinukleotidi koji ih kodiraju
ATE443076T1 (de) Von protease typ ii spaltbares peptid
ATE494301T1 (de) Alpha-fetoprotein-peptide und ihre verwendung
IL149416A0 (en) Human enzymes of the metalloprotease family
NZ591827A (en) Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating immune reaction in a radiotherapy-induced immuno-compromised subject
ATE240349T1 (de) Peptide zur inhibierung von hpv e6-proteinen
ATE503834T1 (de) Bibliotheken rekombinanter chimärischer proteine
ATE441713T1 (de) Tumorantigenprotein und dessen verwendung
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
DE60120187D1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
GB2441941A (en) An isolated recombinant vaccinia virus complement control protein (HRVCP) polypeptide
EP1679372A4 (en) NEW PLEXIN POLYPEPTIDE, THIS CODING DNA AND USE THEREOF
DE60134545D1 (de) Verwendungen von tgap7 zur modulation der aktivierung von leukozyten
HK1083850A1 (en) Peptides binding the phosphatase 2a protein and polynucleotides encoding same
WO2002034882A3 (en) Genes regulating programmed cell death
HK1123813A1 (en) Anti-tumor drug, medicament, composition, and use thereof